Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphisms.
about
Pharmacogenomics: personalizing pediatric heart transplantationPharmacogenetics of treatment response in psoriatic arthritisPersonalized therapeutics: HIV treatment in adolescentsExplaining variability in ciclosporin exposure in adult kidney transplant recipients.Improving the prediction of pharmacogenes using text-derived drug-gene relationships.CYP3A5, ABCB1, and SLCO1B1 polymorphisms and pharmacokinetics and virologic outcome of lopinavir/ritonavir in HIV-infected children.Effect of cytokine and pharmacogenomic genetic polymorphisms in transplantationNo significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin.Clinical and ethical considerations of massively parallel sequencing in transplantation science.Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs.Effect of CYP3A4*22, CYP3A5*3, and CYP3A Combined Genotypes on Cyclosporine, Everolimus, and Tacrolimus Pharmacokinetics in Renal Transplantation.The latest advances in pharmacogenetics and pharmacogenomics in the treatment of psoriasis.Integration of pharmacogenetics and pharmacogenomics in drug development: implications for regulatory and medical decision making in pediatric diseases.Pharmacogenetics and individualized therapy in children: immunosuppressants, antidepressants, anticancer and anti-inflammatory drugs.The role of genetics in drug dosingOntogeny of oral drug absorption processes in children.Pediatric pharmacogenomics: a systematic assessment of ontogeny and genetic variation to guide the design of statin studies in children.Pharmacogenetics in kidney transplantation: recent updates and potential clinical applications.Population pharmacokinetics of cyclosporine in transplant recipients.Pediatric perspective on pharmacogenomics.Use of pharmacogenomics in pediatric renal transplant recipients.Impact of Genetic Polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on Drug Disposition and Potential Clinical Implications: Update of the Literature.Dosing algorithms for initiation of immunosuppressive drugs in solid organ transplant recipients.Impact of CYP3A4 and MDR1 gene (G2677T) polymorphisms on dose requirement of the cyclosporine in renal transplant Egyptian recipients.The potential of steroids and xenobiotic receptor polymorphisms in forecasting cyclosporine pharmacokinetic variability in young kidney transplant recipients.Genotyping NUDT15 can predict the dose reduction of 6-MP for children with acute lymphoblastic leukemia especially at a preschool age.Long-term changes in cyclosporine pharmacokinetics after renal transplantation in children: evidence for saturable presystemic metabolism and effect of NR1I2 polymorphism.Long-term effects of ABCB1 and SXR SNPs on the systemic exposure to cyclosporine in pediatric kidney transplant patients.ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin.Developmental pharmacogenetics of CYP2C19 in neonates and young infants: omeprazole as a probe drug.Pharmacokinetics and dynamics of mycophenolate mofetil after single-dose oral administration in juvenile dachshunds.A drug transporter for all ages? ABCB1 and the developmental pharmacogenetics of cyclosporine.
P2860
Q28081200-963386DE-2167-4CB1-AED7-D638CC6705E0Q28081252-518B02EA-06BC-43C9-94BA-17C2D4BC3E54Q33576926-4773DF0D-DBDF-4C87-98B5-9EEE6259916DQ33847140-424A4848-ADE8-40FD-9EEF-A2C0534D5FE1Q34974251-E7F4467F-4793-4551-AE5E-32FF454676C4Q35113316-1B830166-8916-4003-8ABB-F797EA90424FQ37244838-2290946C-E9CA-4D58-B38A-95FF7D1A9AD1Q37399440-A88D9499-FBF8-4376-A118-7E3257A5BAA7Q37428559-2A6045CB-AB25-46B1-8B37-5B543286D9C6Q37481450-0237909E-FBEC-420A-A687-ED512A854F25Q37620393-34709C75-CF94-4CDD-A644-F3AC171EE706Q37722744-49C5EC16-DC6E-4952-9019-FC30E629BFE3Q37874869-EB1E0B14-23AB-435A-A6C7-2A0C2B5CEDEAQ37892531-B69FC177-8170-4739-BE8A-0308FD8F7CE6Q37987439-67AD10CD-77EF-41BF-BB6A-E3B79E354890Q38017723-AFF7EF46-970B-40A9-889A-FBEC8AA6D819Q38049379-7FEF7318-2A57-4DCD-927B-201AA0C9B781Q38063426-34E1777D-E97B-44ED-A9FB-22D0A70A399CQ38115174-CF31C750-C5B1-4421-BCC0-D237B0BC7BB0Q38162869-7C7A7725-B5F3-44F9-B8BE-9E7008144CDBQ38367819-CD7B54B8-D5B3-49B8-90EB-6B26A5189A35Q38414396-761DFCBB-E20C-42E3-8704-F1B556F3E392Q38417581-555895CA-4489-4FCF-9A81-658A14DE8741Q39452105-91A63878-0973-4BDC-A7DF-248D009EC4C4Q39591103-50439756-D401-482B-8D18-E48E6056A6A4Q39756044-2F5048F6-0BE2-4278-875C-704A2F3CDAD6Q43182515-5B3C8B63-65D3-47C8-95CC-8BB1F64427DFQ44839090-F5EC3DD5-D94C-4065-B736-025B2CFF9A5BQ45993642-9D007788-50A5-4EC9-B259-916877A88DBCQ48151911-5D450101-EF5F-4A65-9F7A-359C81904813Q50561382-A04BC45C-CB30-4DBC-B02C-F3EAC404A111Q51955888-E6C4F8A3-D798-457E-BB23-38134728FED3
P2860
Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphisms.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Pharmacogenetics of cyclospori ...... luence of ABCB1 polymorphisms.
@en
Pharmacogenetics of cyclospori ...... luence of ABCB1 polymorphisms.
@nl
type
label
Pharmacogenetics of cyclospori ...... luence of ABCB1 polymorphisms.
@en
Pharmacogenetics of cyclospori ...... luence of ABCB1 polymorphisms.
@nl
prefLabel
Pharmacogenetics of cyclospori ...... luence of ABCB1 polymorphisms.
@en
Pharmacogenetics of cyclospori ...... luence of ABCB1 polymorphisms.
@nl
P2093
P50
P1476
Pharmacogenetics of cyclospori ...... luence of ABCB1 polymorphisms.
@en
P2093
Janne T Backman
Mats O Karlsson
Pertti J Neuvonen
Samuel Fanta
Siv Jönsson
P356
10.1097/FPC.0B013E3282F3EF72
P577
2008-02-01T00:00:00Z